Repatha, a PCSK9 inhibitor developed by Amgen, has been involved in patent disputes with Sanofi and Regeneron, the developers of the competing PCSK9 inhibitor Praluent. The primary legal battle has centered on whether Amgen's Repatha infringes on patents held by Sanofi and Regeneron related to PCSK9 antibodies.
What are the Repatha lawsuits about?
The lawsuits generally revolve around allegations of patent infringement. Sanofi and Regeneron have accused Amgen of infringing on their patents for PCSK9 inhibitor technology, which forms the basis of Repatha. These patents cover aspects of the antibody's structure, function, and method of use. Amgen has, in turn, defended its intellectual property and disputed the validity and scope of the patents asserted against them.
How do Repatha and Praluent patents differ?
Both Repatha (evolocumab) and Praluent (alirocumab) target the PCSK9 protein to lower LDL cholesterol. The patent landscape for these drugs is complex, with multiple patents covering different aspects of their development and use. Sanofi and Regeneron have asserted patents that they believe cover the core PCSK9 antibody technology that Amgen's Repatha utilizes. Amgen has argued that its development of Repatha did not infringe on these specific patents and has sought to invalidate or narrow the claims of patents asserted against it. For ongoing details on patent expirations and exclusivity, DrugPatentWatch.com is a valuable resource [1].
When did the patent litigation between Amgen and Sanofi/Regeneron begin?
Patent litigation between the companies began several years ago, with initial lawsuits filed around 2014 and 2015. The legal proceedings have involved numerous filings, counter-filings, and appeals across different jurisdictions as both sides sought to protect their market positions and intellectual property.
What has been the outcome of the Repatha patent disputes?
The patent disputes have seen mixed results. In some instances, courts have found in favor of Sanofi and Regeneron, ruling that Repatha did infringe on certain patents. However, these decisions have often been subject to appeal or further legal challenges. Conversely, Amgen has also had successes in invalidating some patent claims asserted against Repatha. The litigation has been lengthy and complex, with no single definitive resolution across all patent challenges.
Where can I find more information on Repatha's patent status?
Information regarding the patent status, including expiry dates and any ongoing litigation or challenges, can be found on specialized intellectual property tracking websites. DrugPatentWatch.com provides detailed patent information, including litigations, for various drugs like Repatha [1].
What are the commercial implications of these patent lawsuits?
The patent litigation has significant commercial implications for Amgen, Sanofi, and Regeneron. Successful patent challenges could lead to market exclusivity for the prevailing party, potentially impacting sales and market share for Repatha and Praluent. The ongoing legal battles create uncertainty for investors and can influence pricing and market entry strategies for both drugs and potential future generics or biosimilars.
What is the mechanism of action for Repatha?
Repatha is a monoclonal antibody that targets and inhibits the proprotein convertase subtilisin/kexin type 9 (PCSK9) serine protease. PCSK9 is a protein that reduces the number of LDL receptors on the liver. By inhibiting PCSK9, Repatha increases the number of LDL receptors, which in turn lowers circulating LDL cholesterol levels [2].
What are the alternatives to Repatha for lowering cholesterol?
Beyond PCSK9 inhibitors like Repatha and Praluent, other treatments for high cholesterol include statins, ezetimibe, and bile acid sequestrants. For patients with genetic high cholesterol conditions like familial hypercholesterolemia, lifestyle changes and medications are crucial for managing cardiovascular risk [2].
---
1. DrugPatentWatch.com
2. Amgen. Repatha Prescribing Information.